• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer

    6/20/23 4:15:00 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTLT alert in real time by email

    Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023.

    Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by Apollo. Previously he was Chief Financial Officer at Superior Industries International and General Cable Corporation.

    "Matti is a proven finance leader whose deep experience growing and driving profitability at publicly traded, complex global manufacturing companies is ideally suited to help Catalent reach its next level of performance, including enhanced profitability and value-creation for shareholders," said Alessandro Maselli, President and Chief Executive Officer of Catalent. "He brings significant expertise and a highly strategic approach that I am confident will make him an invaluable addition to Catalent's executive leadership team as we continue to seize opportunities in the CDMO space."

    Earlier in his career, Mr. Masanovich held finance leadership roles of increasing responsibility in a number of companies in the automotive industry, where he demonstrated a strong history of improvement and profitability and operating efficiency. Mr. Masanovich began his career with PricewaterhouseCoopers LLP. He has Bachelor of Commerce, Finance & Accounting and M.B.A. degrees from the University of Windsor and is a Chartered Accountant in Canada.

    "Catalent is a dynamic company that operates in a critical, fast-growing sector that has a meaningful impact on helping people live longer, healthier lives. I am impressed with their portfolio of solutions and feel the company has the right capabilities to serve that market, and I am excited to work with Catalent's talented team to create value for its customers, patients, and shareholders," said Mr. Masanovich.

    Mr. Masanovich will have responsibility for all aspects of Catalent's global financial operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury. He will also be a member of Catalent's executive leadership team, the highest level of company management.

    About Catalent

    Catalent, Inc. (NYSE:CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent's expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results or achievements to be materially different from Catalent's expectations and projections expressed or implied by the forward-looking statements. Important factors include, but are not limited to, those discussed under the caption "Risk Factors" in Catalent's Annual Report on Form 10-K for the year ended June 30, 2022 (as amended), Catalent's Quarterly Report on Form 10-Q for the three and nine months ended March 31, 2023, and Catalent's other filings with the SEC. Forward-looking statements speak only as of the date of this press release and are based on information available to Catalent as of the date of this press release, and Catalent assumes no obligation to update such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230620980771/en/

    Get the next $CTLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTLT

    DatePrice TargetRatingAnalyst
    11/16/2023$45.00 → $53.00Neutral → Outperform
    Robert W. Baird
    9/5/2023$62.00Hold → Buy
    Argus
    7/20/2023$43.00Equal Weight
    Wells Fargo
    7/5/2023$45.00Neutral
    JP Morgan
    6/14/2023$45.00 → $44.00Buy → Hold
    Jefferies
    5/22/2023$90.00 → $45.00Overweight → Neutral
    JP Morgan
    5/15/2023$55.00 → $29.00Buy → Hold
    Deutsche Bank
    5/8/2023$28.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CTLT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Catalent Inc.

      15-12G - Catalent, Inc. (0001596783) (Filer)

      12/30/24 8:00:08 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Catalent Inc.

      POSASR - Catalent, Inc. (0001596783) (Filer)

      12/18/24 10:38:20 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Catalent Inc.

      S-8 POS - Catalent, Inc. (0001596783) (Filer)

      12/18/24 10:33:58 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Group Pres. Pharma & Consumer Gennadios Aristippos returned 135,286 shares to the company and was granted 21,562 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Catalent, Inc. (0001596783) (Issuer)

      12/18/24 2:10:11 PM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Group President, Biologics Mcerlane David returned 47,730 shares to the company and was granted 11,426 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Catalent, Inc. (0001596783) (Issuer)

      12/18/24 2:07:42 PM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Hatzfeld Michael returned 16,676 shares to the company and was granted 3,144 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Catalent, Inc. (0001596783) (Issuer)

      12/18/24 2:05:24 PM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Catalent Announces New Board Appointments

      Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

      2/20/25 9:00:00 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

      NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health

      12/18/24 5:46:00 PM ET
      $BILL
      $CTLT
      $LII
      $SPGI
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Holdings Completes Acquisition of Catalent

      Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, "The completion of this transaction marks a significant milestone for Catalent.

      12/18/24 8:57:00 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care